NAV-201 / Navrogen - LARVOL DELTA

NAV-201, an orally bioavailable small molecule NK cell activator enhancing antibody-mediated cancer therapies (AACR 2024) - "In vivo, NAV-201 was found to be well tolerated up to at least 120 mg/kg when administered orally and daily to mice, have a serum half-life of 18 hours, enhance systemic levels of the NK cell produced INF-γ and TNF-α cytokines, and enhance the therapeutic efficacy of antibodies in mouse xenografts. Together, these data support the further development of NAV-201 for human testing to improve and/or enhance the efficacy of antibody-based therapies in HIO factor positive cancers."

Oncology • FCGR3A • TNFA